You are here:

MS in the media - 6 May 2016

Published on

30 April - 6 May 2016

These are links to news stories from the last week that may be of interest to people in the UK. The link beneath each item will take you to the original story.

Please note that the MS Trust did not write the original items and does not endorse their content nor any claims made in them.

To keep up to date on all the latest news, views and research on multiple sclerosis, sign up for Open Door, our free newsletter or regular email alerts.

Zinbryta (daclizumab) nears approval in Europe

The committee (CHMP) that advices the European Medicines Agency (EMA) has recommend that they approve daclizumab, a once a month injection for people with relapsing remitting MS.  In trials daclizumab cut relapse rates by about half

Source: Biogen press release

MS Trust link: Daclizumab

Ocrelizumab and progressive MS

An American review of the ongoing research into ocrelizumab as a treatment for primary progressive MS. 

Source: MD News

MS Trust link: Ocrelizumab

Too much sitting is bad for you

Research from Birmingham, says people with MS sit for too long and should be encouraged to move around more if they are able to.

Source: MD Magazine

MS Trust link: Exercise

Yoga and aquatic exercise help MS symptoms

A small study found that women who did yoga or aquatic exercise reported less fatigue, depression and altered sensations than a no exercise control group

Source: Science Daily

MS Trust link: Yoga
MS Trust link: Exercises for people with MS

CCSVI symptoms not unique to MS

A study of people who don't have MS has found that many of them had the same abnormalities in veins that have been linked to CCSVI in people with MS.

Source: Canadian MS Society

MS Trust link: CCSVI

Gilenya (fingolimod) rebound risk

A case review of 46 people stopping Gilenya (fingolimod) found that five of them developed severe symptoms that were more aggressive than their level before starting treatment.  The symptoms appeared within the usual washout period before another treatment is started and persisted despite treatment with steroids. 

Source: MedPage Today

MS Trust link: Gilenya (fingolimod)

Suicide rates higher in MS

Swedish research looked at rates of suicide in a sample of 29,617 people with MS.  There were 423 attempted suicides and 114 completed suicides. The rates for both attempted and successful suicides were roughly twice as high as in a control group of people who do not have MS.

Source: Neurology Advisor

MS Trust link: Depression

Print this page